Media hub

Chiesi Group delivers solid H1 2026 performance, combining growth, continued investment in innovation and positive economic impact across communities

Chiesi advances its Carbon Minimal Inhaler journey as European submissions for its Single Inhaler Triple Therapy (SITT) and ICS/LABA combination next-generation propellant pMDIs are validated

Chiesi receives European Marketing Authorisation for its Single Inhaler Triple Therapy delivered via NEXThaler® for the maintenance treatment of Asthma

Chiesi Returns Seralutinib Rights to Gossamer Bio as Companies Terminate Collaboration and License Agreement

Chiesi Marks Significant Step in its Net Zero Journey with MHRA Approval of its First Pressurized Metered-Dose Inhalers Containing a Next-Generation, Low GWP Propellant

Chiesi and Oak Hill Bio Holdings complete patient enrollment in the Phase 2b FOOTPRINTS study